市場調查報告書
商品編碼
1442910
免疫測定 - 全球市場考量、競爭格局和市場預測 (2030)Immunoassay - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
預計2024-2030年預測期內,全球免疫分析市場規模將以7.53%的複合年增長率大幅成長。免疫分析的需求主要是由癌症等慢性疾病和糖尿病等生活方式疾病的日益普及所推動的。乳癌和攝護腺癌等各種腫瘤疾病的增加是影響市場積極成長的主要因素。此外,人們對疾病早期診斷的認識不斷提高也有助於免疫分析市場在 2024-2030 年預測期內的整體成長。
免疫分析市場動態
根據International Diabetes Federation (IDF) (2021) 的數據,2021 年全球約有 5.37 億 20 至 79 歲的成年人患有糖尿病。根據相同數據,到 2030 年,全球約有 6.43 億人將受到糖尿病的影響。使用免疫分析可以準確檢測與糖尿病相關的各種生物標記物,例如胰島素和C肽。因此,糖尿病盛行率的增加增加了對免疫測定的需求並有助於市場成長。
根據世界衛生組織 (WHO) (2022) 的數據,2020 年全球報告了約 226 萬例乳癌病例、221 萬例肺癌病例和 193 萬例大腸直腸癌病例。因此,肺癌、乳癌和攝護腺癌等成人癌症病例數量的不斷增加,以及醫生建議每年對這些疾病進行生物標記檢測,正在推動免疫分析市場的發展,這就是前景。
此外,HIV、肝炎等傳染病發生率的上升也是免疫分析市場的主要驅動因素之一。根據世界衛生組織 (WHO) (2022) 的數據,預計 2022 年全球約有 3.54 億人感染乙型或C型肝炎。因此,傳染病患者數量的增加將進一步增加對診斷的需求並有助於市場成長。
然而,與免疫檢測試劑盒和儀器相關的技術問題、高成本以及缺乏執行這些複雜測試所需的熟練專業人員可能會限制免疫檢測市場的成長,並成為一個障礙。
免疫分析市場細分分析
在免疫分析市場的產品領域,試劑和試劑盒類別預計將在 2023 年獲得可觀的收入佔有率。這是由於世界各地慢性病和傳染病的增加以及免疫測定測試數量的增加,對免疫測定試劑盒和試劑的需求和消耗量很高。此外,免疫檢測試劑盒所提供的各種優勢,例如高靈敏度和強特異性也是促進此細分市場成長的因素之一。
此外,每次測試都需要試劑盒和試劑,使它們成為測試過程中不可或缺的一部分。
此外,隨著這一領域的需求不斷增加,許多新產品正在引入市場。2021 年 2 月,Agilent Technologies推出了 Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay(ELISA),用於檢測人類血清或血漿中針對 SARS-CoV-2 的免疫球蛋白 G (IgG) 抗體。
因此,由於上述因素,預計試劑和試劑盒類別將顯著成長,推動整個免疫分析市場在預測期內的成長。
預計北美將主導整個免疫分析市場。
在所有地區中,預計到 2023 年北美將佔免疫分析市場的最大佔有率。這被認為是由於該地區存在不健康的生活習慣,以及大量患有糖尿病、甲狀腺疾病等各種生活方式相關疾病的患者。此外,消費者對疾病診斷的高度認識、政府支持以及產品開發和上市的優勢也是影響該地區市場成長的因素。
本報告提供了全球免疫分析市場的研究和分析,包括市場規模和預測、驅動因素和挑戰以及公司和產品概況。
Immunoassay Market By Product (Reagents & Kits And Instruments), Technology (Radioimmunoassay, Enzyme-Linked Immunoassay, Chemiluminescence Immunoassay, Fluoroimmunoassay, And Others), Sample (Blood, Urine, Saliva, And Others), Application (Oncology, Cardiology, Infectious Disease Testing, Endocrinology, Autoimmune Disorders, And Others), End-User (Hospitals & Clinics, Diagnostic Labs, Pharmaceuticals & Biotech Industries, And Others), and geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of chronic diseases such as cancer, lifestyle diseases such as diabetes mellitus, and others, and the growing prevalence of infectious diseases such as hepatitis, hiv, and others
The global Immunoassay market is poised for significant growth, projected to achieve a remarkable Compound Annual Growth Rate (CAGR) of 7.53% during the forecast period from 2024 to 2030. The demand for immunoassay is primarily being boosted by the increasing prevalence of chronic disorders such as cancers, and lifestyle disorders such as diabetes mellitus, among others. The increase in various oncological disorders such as breast cancer and prostate cancer is a key factor influencing the positive growth of the market. Further, the rising awareness among people regarding early disease diagnosis is also contributing to the overall growth of the immunoassay market during the forecast period from 2024-2030.
Immunoassay Market Dynamics:
As per the International Diabetes Federation (IDF) 2021, worldwide around 537 million adults aged between 20 and 79 years had diabetes in the year 2021. Also, according to the same source around 643 million people will be suffering from diabetes by 2030, globally. The various biomarkers associated with diabetes mellitus such as insulin and C-peptide can be detected accurately with immunoassay. Thus, the rising prevalence of diabetes will increase the demand for immunoassay, thereby contributing to its market growth.
As per the World Health Organization (WHO) 2022, there were around 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, and 1.93 million cases of colon and rectal cancer, reported in the year 2020 globally. Therefore, the rising cases of cancers such as lung, breast, and prostate cancer amongst the adult population as well as the recommendation of annual tests for biomarkers of these diseases by doctors is going to accelerate the market for immunoassay.
Further, the rising cases of infectious disorders such as HIV, hepatitis, and others is another key driver for the immunoassay market, as immunoassays are widely used for the diagnosis of infectious disorders. According to the World Health Organization (WHO) 2022, it was estimated that in 2022, around 354 million people were living with Hepatitis B or C infections, globally. Therefore, the increasing cases of infectious diseases will further increase the demand for diagnosis, thus contributing to market growth.
However, technical issues associated with the immunoassay test kits and instruments, high costs, along with the lack of skilled professionals required to perform these complicated tests are some of the market barriers that may restrict the growth of the immunoassay market.
Immunoassay Market Segment Analysis:
Immunoassay Market by Product (Reagents & Kits and Instruments), Technology (Radioimmunoassay, Enzyme-Linked Immunoassay, Chemiluminescence Immunoassay, Fluoroimmunoassay, and Others), Sample (Blood, Urine, Saliva, and Others), Application (Oncology, Cardiology, Infectious Disease Testing, Endocrinology, Autoimmune Disorders, and Others), End-User (Hospitals & Clinics, Diagnostic Labs, Pharmaceuticals & Biotech Industries, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product segment of the Immunoassay market, the reagents & kits category is expected to amass a significant revenue share in the year 2023. This can be attributed to the high demand and consumption of immunoassay kits and reagents and the increasing number of immunoassay tests performed, due to the increasing number of chronic and infectious disorders around the globe. Additionally, various advantages provided by immunoassay kits such as high sensitivity and strong specificity are also some of the factors contributing to the growth of the segment.
Further, the kits and reagents are required for every test making them an integral part of the testing process.
Furthermore, with the growing demand for this segment, numerous new products are being launched in the market. In February 2021, Agilent Technologies launched the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit, which is used for the detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma.
Therefore, owing to the above-mentioned factors, the reagents & kits category is expected to register significant growth, thereby driving the growth of the overall Immunoassay market during the forecast period.
North America is expected to dominate the overall Immunoassay Market:
Among all the regions, North America is estimated to account for the largest share of the Immunoassay market in the year 2023. This can be attributed to the presence of unhealthy lifestyles in the region contributing to a large patient pool suffering from various lifestyle disorders such as diabetes mellitus and thyroid diseases. Additionally, high consumer awareness regarding disease diagnosis, government support, and a dominant market in terms of product development and launches are among other factors influencing the growth of the market in the region.
One of the prominent factors supporting the growth of the North America immunoassay market is the extensive use of immunoassay in the detection of tumor markers indicating cancer development. For instance, according to National Cancer Institute 2020, it was estimated that around 1,806,590 cancer cases were diagnosed in the year 2020 in the United States. Additionally, as per the same source prostate, lung, and colorectal cancer accounted for 43% of the cancer cases in men, and breast, lung, and colorectal making up to 50% of cancer cases in women.
Further, according to the data provided by The Government of Canada 2021, cancer is one of the leading causes of death in Canada. In 2021, around 229,200 Canadians were diagnosed with cancer and 84,600 people died from cancer in Canada. This indicates the huge need for early detection of the diseases, therefore leading to the growth of immunoassay market in the region.
Moreover, the rise in chronic and cardiovascular diseases such as coronary artery diseases, and stroke among the US population is another driver of the immunoassay market. For instance, according to the Centers for Disease Control and Prevention (CDC) 2022, around 18.2 million people aged 20 or above had coronary artery disease in the United States. Also, as per the same source around 805,000 people face heart attacks every year in the United States. This indicates the huge need for immunoassay for the detection of cardiac markers assisting in the identification of cardiovascular disorders and therefore leading to market growth of immunoassay.
Therefore, the factors mentioned above, and the increasing awareness of people regarding early disease diagnosis in the region are some of the important factors which are thereby responsible for driving the market in North America during the forecast period.
Immunoassay Market Key Players:
Some of the key market players operating in the immunoassay market include Beckman Coulter, Inc., Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermofisher Scientific, ALPCO, Autobio, PHC Corporation, Trivitorn Healthcare, Werfen, Danaher Corporation, Sysmex Corporation, Awareness Technology Inc, ZECEN Biotech Co., Quidel Corporation, among others.
Recent Developmental Activities in the Immunoassay Market:
Key Takeaways from the Immunoassay Market Report Study
Target Audience who can be benefited from this Immunoassay Market Report Study
Frequently Asked Questions for the Immunoassay Market:
Immunoassays are bioanalytical methods that usually employ the specificity of antigen-antibody reactions to detect the target molecules in the samples. These are highly specific and sensitive and the reagents used are antibodies and purified antigens, which contribute to their great specificity.
The global Immunoassay market is poised for significant growth, projected to achieve a remarkable Compound Annual Growth Rate (CAGR) of 7.53% during the forecast period from 2024 to 2030.
The immunoassay market is slated to witness prosperity owing to factors such as the growing prevalence of chronic diseases such as cancers, thyroid diseases, lifestyle disorders such as diabetes mellitus, and others. Additionally, there is a large patient pool suffering from various cardiovascular and autoimmune disorders globally. Further, the rising awareness of health, the growing focus on improving accuracy, affordability, portability, and usability of immunoassay for end-users are expected to result in the appreciable revenue growth of the immunoassay market during the forecast period (2024-2030).
Some of the key market players operating in the Immunoassay market include Beckman Coulter, Inc., Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermofisher Scientific, ALPCO, Autobio, PHC Corporation, Trivitorn Healthcare, Werfen, Danaher Corporation, Sysmex Corporation, Awareness Technology Inc., ZECEN Biotech Co., Quidel Corporation, among others.
North America is expected to dominate the overall Immunoassay Market during the forecast period from 2024 to 2030. Due to the presence of a large patient pool associated with various diseases such as diabetes mellitus, and cardiovascular diseases this can be further attributed to the poor lifestyle of people. Further, the region has a very potent market for product development and launches, a high level of consumer knowledge regarding new market launches, support from the government, and the presence of local and significant market players.